Market News & Trends
Paratek Pharmaceuticals Announces Positive Top Line Data From Pilot Efficacy Study for the Treatment of Pulmonary Anthrax & Acceptance of the Second Procurement of NUZYRA Under BARDA Project BioShield
Paratek Pharmaceuticals, Inc. recently announced positive top line data from a pilot rabbit efficacy study evaluating NUZYRA’s effectiveness in the treatment of pulmonary anthrax. In the study, a 100% survival rate….
Assembly Biosciences Announces Promising Interim Results from Two Clinical Trials Evaluating Highly Potent Next-Generation Core Inhibitor Candidates
Assembly Biosciences, Inc. recently announced promising interim efficacy, safety and pharmacokinetic (PK) results from two ongoing clinical studies of its investigational next-generation HBV core inhibitors,…
F2G Announces FDA Filing Acceptance of NDA for Olorofim for the Treatment of Invasive Fungal Infections
F2G Inc. recently announced the US FDA has accepted for filing its New Drug Application (NDA) for olorofim for the treatment of invasive fungal infections…
Adagene Announces Clinical Trial Collaboration to Evaluate Anti-CTLA-4 SAFEbody ADG126 in Combination With Roche’s Standard-of-Care for First-Line Advanced Liver Cancer
Adagene Inc. recently announced a clinical trial collaboration with Roche to evaluate the triple combination of Adagene’s ADG126 with Roche’s atezolizumab and bevacizumab in first-line treatment of….
Ocugen Announces Phase 3 Confirmatory Clinical Trial Agreement for NeoCart
Ocugen, Inc. recently announced the US FDA agreed to Ocugen’s proposed control and overall design for the Phase 3 study of NeoCart, a regenerative cell…
Tarsus Announces Positive Topline Data from Phase 1b Callisto Trial & Initiates Phase 2a Carpo Human Tick Kill Trial Evaluating TP-05, a Novel, Oral Therapeutic for the Prevention of Lyme Disease
Tarsus Pharmaceuticals, Inc. recently announced positive topline results from the completed Phase 1b Callisto trial and the enrollment of the first subject in the Carpo Phase 2a trial…..
Synlogic Announces Achievement of Proof of Concept for SYNB8802 in Enteric Hyperoxaluria Based on Urinary Oxalate Lowering in Phase 1b Study
Synlogic, Inc. recently announced that SYNB8802 has demonstrated proof of concept through clinically significant lowering of urinary oxalate in a Phase 1b study in patients…
Catalent to Expand Its Biologics Analytical Services With New Facility in North Carolina
Catalent recently announced it is to establish a new biologics analytical center of excellence in Durham, within North Carolina’s Research Triangle, to offer comprehensive stand-alone…
MoonLake Immunotherapeutics Screens First Patient in Phase 2 Study of the Nanobody Sonelokimab in Active Psoriatic Arthritis
MoonLake Immunotherapeutics AG recently announced the first subject has been screened in the US in a Phase 2 clinical study of the Nanobody sonelokimab in patients with….
Urica Therapeutics Expands Exclusive License Agreement With Fuji Yakuhin Co. Ltd.
Urica Therapeutics, Inc. recently announced it has expanded its exclusive license agreement with Fuji Yakuhin Co. Ltd. for the development of dotinurad to include the…
Avidity Announces Positive AOC 1001 Phase 1/2 MARINA Data Demonstrating First-Ever Successful Targeted Delivery of RNA to Muscle - Revolutionary Advancement for the Field of RNA Therapeutics
Avidity Biosciences, Inc. recently announced positive AOC 1001 data from the preliminary assessment of the Phase 1/2 MARINA trial demonstrating the first-ever….
Hovione & GEA announce a Strategic Collaboration to Advance Continuous Tableting
Hovione & GEA recently announced a strategic collaboration to advance Continuous Tableting. This partnership stemmed from a successful customer-supplier relationship spanning several years….
Syneos Health Extends Partnership With Medable; Continued Collaboration Will Accelerate Bringing Clinical Trials Closer to the Patient
Syneos Health recently announced it has extended its strategic partnership with Medable, the industry-leading technology platform for patient-centered clinical trials, as part of….
Immix Biopharma Announces Patient Dosing in Ongoing Phase 1b/2a IMX-110 Monotherapy Clinical Trial
Immix Biopharma, Inc. recently announced patient dosing in its ongoing Phase 1b/2a IMX-110 monotherapy clinical trial. This is the 15 patient dosed with IMX-110 to-date.…
Sosei Heptares Receives $10-Million Milestone Payment in Discovery Collaboration With AbbVie Targeting Inflammatory Diseases
Sosei Group Corporation recently announced it has reached an important R&D milestone under its discovery collaboration with AbbVie, the global biopharmaceutical company, focused on inflammatory and autoimmune….
Indaptus Therapeutics Announces Initiation of First-In-Human, Open Label, Dose Escalation & Expansion Multicenter Phase 1 Clinical Trial of Decoy20 in Patients With Advanced Solid Tumors
Indaptus Therapeutics, Inc. recently announced the initiation of INDP-D101, its first-in-human, open-label, dose escalation and expansion, multicenter Phase 1 clinical trial of its lead compound…
Starton Therapeutics’ STAR-LLD Continuous Delivery Shows Superior Tumor Reduction & Progression Free Survival Compared to Pulsatile Lenalidomide Treatment in Lenalidomide-Resistant Model
Starton Therapeutics Inc. recently announced results from a 28-day efficacy study of STAR-LLD continuous subcutaneous (SC) infusion versus intraperitoneal (IP) lenalidomide in immunomodulatory drug (IMiD)-resistant…
Lantheus Grants Rights for the Use of its Microbubbles to SonoThera for its Ultrasound-Guided Nonviral Gene Therapy Platform
Lantheus Holdings, Inc. recently announced a strategic collaboration with SonoThera, Inc. in which Lantheus’ microbubbles will be used in combination with SonoThera’s ultrasound-guided, nonviral, gene…
Caribou Biosciences Selects ROR1 as the Target for CB-020, an iPSC-Derived Allogeneic CAR-NK Cell Therapy
Caribou Biosciences, Inc. recently announced target selection for CB-020, an induced pluripotent stem cell (iPSC)-derived allogeneic anti-ROR 1 (receptor tyrosine kinase like orphan receptor 1)…
UM171 Cell Therapy Demonstrates Improved Outcomes Compared to Cord & Matched Unrelated Donor Peripheral Blood Transplants in Real-World Setting
ExCellThera Inc. recently announced findings from a safety and efficacy retrospective analysis comparing outcomes of patients treated with ECT-001 (UM171-expanded) Cell Therapy in a Phase 1/2 trial to those treated with….
